Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Boehringer Ingelheim prepares schizophrenia app for FDA submission after trial results

Summary by STAT
HANOVER, N.H. — Boehringer Ingelheim this week provided more details about a late stage clinical trial of an app designed to treat under-addressed symptoms of schizophrenia and revealed the company is preparing to submit the app to the Food and Drug Administration for clearance. Developed with Click Therapeutics, the app, CT-155, is a 16-week treatment that adapts key elements of established face-to-face psychosocial treatments for schizophrenia…

1 Articles

STATSTAT
Center

Boehringer Ingelheim prepares schizophrenia app for FDA submission after trial results

HANOVER, N.H. — Boehringer Ingelheim this week provided more details about a late stage clinical trial of an app designed to treat under-addressed symptoms of schizophrenia and revealed the company is preparing to submit the app to the Food and Drug Administration for clearance. Developed with Click Therapeutics, the app, CT-155, is a 16-week treatment that adapts key elements of established face-to-face psychosocial treatments for schizophrenia…

·Boston, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

STAT broke the news in Boston, United States on Friday, December 5, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Hanover, New Hampshire icon

Hanover, New Hampshire

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal